Cost-Effective Analysis of Aspirin and Clopidogrel Therapy in Hospitalized Ischemic Stroke Patients at Mataram City Hospital

Ischemic stroke is one of the diseases with the highest death cases in Indonesia. So stroke patients often need further treatment and long-term rehabilitation. To determine the cost-effectiveness and therapy of aspirin and clopidogrel in ischemic stroke patients by looking at the GCS score of hospitalization at Mataram City Hospital, and to determine the most cost-effective therapy based on ACER and ICER. The research method used was observational descriptive and data collection was carried out retrospectively through patient medical records and financial details data. The sample met the inclusion criteria of 78 people, the sample was analyzed quantitatively by the Independent sample t-test analysis method. The results showed that the total cost of treatment for ischemic stroke patients treated with antiplatelets was the highest in the VIP class clopidogrel group of Rp 5,400,015 and VIP class aspirin Rp 4,982,370 The increase in the highest GCS score of aspirin in class ll was 2.84 and clopidogrel class lll was 2.45. The most cost-effective ACER values of all antiplatelet treatment classes are aspirin VIP class Rp 2,129,218, class l Rp 1,785,451, class ll Rp 1,700,509, class lll Rp 1,380,574 and ICER value in class l Rp -1,993,315 and class lll Rp -1,555,950. The ACER scores of all treatment classes showed that aspirin had the lowest scores. Based on sensitivity analysis and tornado diagrams, clopidogrel showed higher results so that aspirin was more cost-effective than clopidogrel. The use of aspirin antiplatelets was more cost-effective than clopidogrel from all direct medical cost data of ischemic stroke patients